Apelin-12

For research use only. Not for therapeutic Use.

  • CAT Number: I044259
  • CAS Number: 229961-08-4
  • Molecular Formula: C64H103N21O14S
  • Molecular Weight: 1422.70
  • Purity: ≥95%
Inquiry Now

Apelin-12 is one of the most potent C-terminal fragments of the polypeptide that possesses a high affinity to orphan receptor APJ receptor. Apelin-12 is involved in the regulation of body fluid homeostasis and in the central control of feeding. Apelin-12 blocks HIV-1 entry through APJ receptor. Apelin-12 exerts neuroprotective effect[1][2][3].
Apelin-12 (A12) exerts neuroprotective effect against ischemia-reperfusion injury by inhibiting JNK and p38 MAPK signaling pathway in mouse[1].
Administration of exogenous A12 reduces arterial blood pressure in anesthetized rats due to activation of endothelial nitric oxide synthase and exerts a positive inotropic action in failing myocardium of rodents[2].
Apelin-12 stimulates acid secretion through an increase of histamine release in rat stomachs[4].


Catalog Number I044259
CAS Number 229961-08-4
Molecular Formula C64H103N21O14S
Purity ≥95%
Reference

[1]. Pisarenko OI, et al. Effects of structural analogues of apelin-12 in acute myocardial infarction in rats. J Pharmacol Pharmacother. 2013;4(3):198-203.
 [Content Brief]

[2]. Pisarenko OI, et al. Apelin-12 and its structural analog enhance antioxidant defense in experimental myocardial ischemia and reperfusion. Mol Cell Biochem. 2014;391(1-2):241-250.
 [Content Brief]

[3]. Liu DR, et al. Apelin-12 exerts neuroprotective effect against ischemia-reperfusion injury by inhibiting JNK and P38MAPK signaling pathway in mouse. Eur Rev Med Pharmacol Sci. 2018;22(12):3888-3895. Liu DR, et al. Apelin-12 exerts neuroprotective effect against ischemia-reperfusion injury by inhibiting JNK and P38MAPK signaling pathway in mouse. Eur Rev Med Pharmacol Sci. 2018;22(12):3888-3895.
 [Content Brief]

[4]. Ohno S, et al. Apelin-12 stimulates acid secretion through an increase of histamine release in rat stomachs. Regul Pept. 2012;174(1-3):71-78.
 [Content Brief]

Request a Quote